Atlas Trials

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Clinical trial NCT02811159 · TERMINATED

Trial details

NCT number
NCT02811159
Sponsor
Repros Therapeutics Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Uterine Fibroids
Start date
2016-07-26
Primary completion
2017-05-04
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.